Tumor Necrosis Factor Alpha Inhibitors Market Research Report: By Drug (Humira, Remicade), By Disease Type (Alzheimer's Diseases, Multiple Sclerosis), By Route Of Administration, By Stage Of Clinical Trials, By Application – Global Forecast Till 2027

Tumor Necrosis Factor Alpha Inhibitors Market - Overview

The tumor necrosis factor alpha (TNF-a) inhibitors signify one of the major treatment techniques for inflammatory diseases. Globally, this drug class is known to be the most effective drugs in the overall pharmaceutical industry. Several conditions such as inflammations, rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and seronegative spondyloarthropathies, can be treated with the help of these drugs. The total sales of the top three blockbuster TNF-alpha inhibitors namely Remicade, Enbrel, and Humira had surpassed USD 32 billion in 2016.

In the present scenario, developing countries have stringent regulatory requirements for approval of a new drug. It is a difficult task for marketing authorization application to get single regulatory for a new drug product which belongs to various categories of drugs such as NCE, biologicals, controlled drugs, etc. Therefore, the knowledge of precise and detailed regulatory requirements for market authorization application of different categories of drugs should be known to establish a suitable regulatory strategy. There is a need for pronounce and a fine balance between the persistence of gaining market access to pharmaceuticals, to protect the public health and facilitate healthy growth of pharmaceutical manufacturers.

The global tumor necrosis factor alpha inhibitors market is expected to grow at a CAGR of approximately 7.1% during the forecast period 2017-2023.

Request Free Sample Copy at: https://www.marketresearchfuture.com/sample_request/5538

Tumor Necrosis Factor Alpha Inhibitors Market - Competitive Analysis

The global tumor necrosis factor alpha inhibitors market is expected to grow at a CAGR of approximately 7.1% during the forecast period 2017-2023.

According to the National Health Interview Survey, in 2016, almost 20% of the global population was reported to be suffering from chronic pain, with rheumatoid arthritis being one of the major reasons. Moreover, according to the Centre for Disease Control and Prevention, by 2040, approximately 78 million (26%) of the U.S. adults are projected to have arthritis. These reasons owe to an Increase consumption of Tumour Necrosis Factor Alpha inhibitor drugs. Favourable re-imbursement policies and availability of high end medical amenities make America leading player in Tumor Necrosis Factor Alpha Inhibitors Market.

The anti TNF Drugs (Humira, Remicade & Enbrel) for Rheumatic Disease have combined sales of more than US$ 30 Billion in 2015 A US-based company, P2D Biosciences received $ 2.3 million fund from NIH (National Institutes of Health) with four grants. The grants include the development of new drugs for the treatment of acute leukaemia and alzheimer's disease and another new drug to improve stem cell transplant therapy for treating leukemia and lymphomas, which will help P2D in develop medical aids that improve the lives and health of people who are affected with these diseases.

In May 2016, Pfizer acquired Anacor because of its inflammatory & immunology product portfolio. Anacor is a biopharmaceutical company focused on small molecule therapeutics from its boron chemistry platform, and its brain child Crisaborole is in FDA review .Upon its approval; it will be a first-line treatment option for patients with atopic dermatitis. Anacor has one more drug AN2898 (5-(3,4-dicyanophenoxy)-1-hydroxy -1,3-dihydro-2,1-benzoxaborole) in its pipeline which inhibits the action of TNF alpha and phosphodiesterase 4. Approval of the same drug by FDA will have a positive impact on the economy of the company as well as increasing tits share in global TNF alpha inhibitor market.

In 2016 Intas Biopharmaceuticals an Indian company headquatered in Ahmedabad launched Etanercept biosimilar – Intacept which is TNF alpha inhibiting drug. This is biologic drug and hence less costly than the innovator drug.

Tumor Necrosis Factor Alpha Inhibitors Market - Regional Analysis

The global tumor necrosis factor alpha inhibitors market is segmented as the Americas, Europe, Asia Pacific and the Middle East and Africa.

The Americas is projected to hold the largest share of the global tumor necrosis factor alpha inhibitors market. P2D Biosciences, a US-based company, received $ 2.3 million funding from NIH (National Institutes of Health) with four grants. The grants include the development of new drugs for the treatment of acute leukemia and Alzheimer's disease and a new drug to improve stem cell transplant therapy for treating leukemia and lymphomas, which will help P2D to develop medical advances that improve the lives and health of people who are affected with these diseases.

Europe is expected to capture the second lead in this market in the coming five years owing to substantial technological advancements. In 2016, LEO Pharma, a Denmark based company entered biologics through a strategic partnership with AstraZeneca. The partnership will help LEO Pharma enhance their product portfolio. A strategic alliance with a healthcare giant will help LEO pharma expand their geographic presence and become a world leader in dermatology segment.

Moreover, Asia Pacific is expected to witness the fastest growth rate over the forecast period. The Middle East and Africa are also expected to show healthy growth in the coming five years.

Browse Detailed TOC with COVID-19 Impact Analysis at: https://www.marketresearchfuture.com/reports/tumor-necrosis-factor-alpha-inhibitors-market-5538

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact:

Akash Anand

Market Research Future

+1 646 845 9312

Email: [email protected]